NextCure (NASDAQ:NXTC) Trading 7.7% Higher

NextCure Inc (NASDAQ:NXTC)’s stock price traded up 7.7% on Thursday . The company traded as high as $9.60 and last traded at $9.48. 800,937 shares changed hands during mid-day trading, an increase of 69% from the average session volume of 472,721 shares. The stock had previously closed at $8.80.

A number of equities analysts have weighed in on the stock. ValuEngine raised shares of NextCure from a “hold” rating to a “buy” rating in a research report on Monday, July 13th. Morgan Stanley cut shares of NextCure from an “overweight” rating to an “equal weight” rating and set a $11.00 price objective for the company. in a research report on Monday, July 13th. Benchmark raised shares of NextCure from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research report on Thursday, July 16th. Piper Sandler decreased their price objective on shares of NextCure from $87.00 to $32.00 in a research report on Monday, July 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective on shares of NextCure in a research report on Friday, August 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company’s stock. NextCure currently has an average rating of “Hold” and a consensus price target of $30.64.

The stock has a market capitalization of $242.15 million, a P/E ratio of -10.42 and a beta of -0.55. The company’s 50-day simple moving average is $9.00 and its 200-day simple moving average is $22.43. The company has a debt-to-equity ratio of 0.01, a current ratio of 37.68 and a quick ratio of 37.68.

NextCure (NASDAQ:NXTC) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.03). NextCure had a negative net margin of 65.22% and a negative return on equity of 8.43%. On average, analysts forecast that NextCure Inc will post -1.31 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in NXTC. UBS Group AG grew its stake in NextCure by 1,564.2% during the first quarter. UBS Group AG now owns 9,153 shares of the company’s stock worth $339,000 after buying an additional 8,603 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of NextCure by 10.6% in the first quarter. Rhumbline Advisers now owns 17,365 shares of the company’s stock worth $644,000 after acquiring an additional 1,671 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of NextCure by 12.9% in the first quarter. Bank of New York Mellon Corp now owns 49,852 shares of the company’s stock worth $1,848,000 after acquiring an additional 5,692 shares during the last quarter. State Street Corp lifted its holdings in shares of NextCure by 7.7% in the first quarter. State Street Corp now owns 448,844 shares of the company’s stock worth $16,639,000 after acquiring an additional 32,282 shares during the last quarter. Finally, BNP Paribas Arbitrage SA lifted its holdings in shares of NextCure by 277.8% in the first quarter. BNP Paribas Arbitrage SA now owns 6,173 shares of the company’s stock worth $229,000 after acquiring an additional 4,539 shares during the last quarter. Hedge funds and other institutional investors own 73.59% of the company’s stock.

About NextCure (NASDAQ:NXTC)

There is no company description available for NextCure Inc

Featured Article: Balance Sheet

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.